Kiniksa Pharmaceuticals International PLC
KNSA43.090USD
+0.510+1.20%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.25BMarket Cap
88.60P/E TTM
More Details of Kiniksa Pharmaceuticals International PLC Company
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Kiniksa Pharmaceuticals International PLC Info
Ticker SymbolKNSA
Company nameKiniksa Pharmaceuticals International PLC
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Number of employees315
Security typeOrdinary Share
Fiscal year-endMay 24
Address23 Old Bond Street, Floor 3
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWIS 4PZ
Phone
Websitehttps://www.kiniksa.com/
Ticker SymbolKNSA
IPO dateMay 24, 2018
CEOPatel (Sanjiv K)
Company Executives of Kiniksa Pharmaceuticals International PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
109.80K
-111794.00%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+9373.00%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
19.16K
+683.00%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
19.09K
-12000.00%
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
16.67K
-6048.00%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
109.80K
-111794.00%
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
--
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
61.32K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+9373.00%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
19.16K
+683.00%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
19.09K
-12000.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
180.71M
99.92%
United Kingdom
146.00K
0.08%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.86%
The Vanguard Group, Inc.
6.88%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
Other
68.93%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.86%
The Vanguard Group, Inc.
6.88%
Baker Bros. Advisors LP
6.25%
Tang Capital Management, LLC
5.16%
Fairmount Funds Management LLC
3.93%
Other
68.93%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.20%
Investment Advisor/Hedge Fund
23.90%
Investment Advisor
19.42%
Research Firm
7.63%
Individual Investor
3.31%
Pension Fund
0.48%
Bank and Trust
0.18%
Family Office
0.10%
Corporation
0.02%
Other
3.74%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
449
42.30M
93.67%
-4.53M
2025Q3
419
40.93M
90.64%
-3.92M
2025Q2
396
42.64M
98.10%
-1.50M
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
4.00M
8.86%
+90.19K
+2.31%
Sep 30, 2025
The Vanguard Group, Inc.
3.06M
6.77%
-68.47K
-2.19%
Sep 30, 2025
Baker Bros. Advisors LP
2.82M
6.25%
--
--
Sep 30, 2025
Tang Capital Management, LLC
2.33M
5.16%
--
--
Sep 30, 2025
Fairmount Funds Management LLC
1.77M
3.93%
--
--
Sep 30, 2025
Acadian Asset Management LLC
1.62M
3.58%
+350.53K
+27.64%
Sep 30, 2025
D. E. Shaw & Co., L.P.
1.13M
2.51%
+342.88K
+43.33%
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
1.07M
2.37%
+332.85K
+45.26%
Sep 30, 2025
Desnick (Robert)
1.05M
2.33%
--
--
Apr 08, 2025
Millennium Management LLC
1.01M
2.25%
-5.84K
-0.57%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.14%
First Trust Active Factor Small Cap ETF
0.7%
iShares Health Innovation Active ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.22%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.21%
WisdomTree US SmallCap Fund
0.21%
WisdomTree US SmallCap Quality Growth Fund
0.18%
Invesco Nasdaq Biotechnology ETF
0.16%
Fidelity Enhanced Small Cap ETF
0.14%
Strive Small-Cap ETF
0.07%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.14%
First Trust Active Factor Small Cap ETF
Proportion0.7%
iShares Health Innovation Active ETF
Proportion0.38%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.21%
WisdomTree US SmallCap Fund
Proportion0.21%
WisdomTree US SmallCap Quality Growth Fund
Proportion0.18%
Invesco Nasdaq Biotechnology ETF
Proportion0.16%
Fidelity Enhanced Small Cap ETF
Proportion0.14%
Strive Small-Cap ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
